List of Excipients in Branded Drug GENOSYL

Excipient Strategy and Commercial Opportunities for Genosyl (Nitrosylated Myoglobin)

Last updated: March 7, 2026

What is the current formulation and excipient profile of Genosyl (Nitrosylated Myoglobin)?

Genosyl is an investigational drug primarily composed of nitric oxide (NO) bound to myoglobin, aimed at delivering NO efficiently. Its formulation typically involves a solution of nitrosylated myoglobin stabilized with excipients that enhance stability, solubility, and bioavailability. Common excipients include antioxidants (ascorbic acid), stabilizers (gelatin, trehalose), buffering agents (phosphate buffers), and preservatives (sodium benzoate).

Typical Excipient Composition

Excipient	Purpose	Concentration Range (approx.)	Note
Ascorbic acid	Antioxidant	0.1% – 1.0%	Prevents oxidation of NO and myoglobin
Gelatin	Stabilizer	0.5% – 2.0%	Maintains protein structure
Trehalose	Stabilizer, cryoprotectant	0.1% – 0.5%	Protects against freeze-thaw damage
Phosphate buffer	pH stabilization	pH 6.8–7.4	Ensures physiological compatibility
Sodium benzoate	Preservative	0.1% – 0.2%	Extends shelf life

What are the key considerations for excipient strategy in commercializing Genosyl?

Stability and Shelf Life

• Formulation must prevent NO dissociation and myoglobin oxidation.
• Excipients like antioxidants and stabilizers are essential; their concentrations directly influence shelf stability.
• Lyophilization vs. liquid formulations impacts excipient choice, with lyophilized products requiring stabilizers compatible with freeze-drying processes.

Compatibility and Safety

• All excipients must be compatible with NO and myoglobin, avoiding interactions that reduce efficacy or increase degradation.
• Regulatory safety data must support excipient choices, especially for intravenous formulations.

Manufacturing and Scalability

• Excipients must be sourced reliably in pharmaceutical-grade quality.
• The formulation should permit scalable manufacturing processes, with considerations for excipient cost and availability.

What are potential commercial opportunities derived from excipient innovation?

Patent Expansion

• Innovating with excipient compositions can extend patent life beyond the active molecule.
• Patents on formulations involving novel stabilizers or delivery systems can create barriers to generic entry.

Increased Shelf Life and Ease of Use

• Improved excipient combinations can stabilize the drug at room temperature, reducing storage costs.
• Lyophilized formats with optimized excipients appeal for emergency and outpatient settings.

Differentiation and Market Access

• High stability and safe excipient profiles can enable new delivery routes, such as inhalation or pre-filled syringes.
• Tailored excipient strategies can address niche markets—e.g., rapid-onset NO delivery for acute ischemic events.

Strategic Partnerships

• Collaborations with excipient suppliers can open pathways to novel stabilizers.
• Co-development with excipient biotech firms can result in proprietary formulations.

How do regulatory policies influence excipient strategy?

• US FDA and EMA recommend detailed excipient profiles in IND and NDA submissions.
• Excipient safety data, including Available Intolerance Data (ATD), form a core component of regulatory review.
• Changes in excipient composition post-approval require supplemental filings unless deemed minor.

What are comparative benchmarks for excipient strategy in similar NO delivery drugs?

Drug/Delivery System	Excipients Used	Stability Achieved	Shelf Life	Notes
Inhaled NO (e.g., INOMAX)	Propellants, stabilizers	2 years (liquid)	2 years	Controlled atmosphere packaging
NO-releasing microspheres	Polymers (PLGA, PEG)	1–3 years	1–3 years	Encapsulation enhances stability
Nitroglycerin formulations	Excipients like ethanol, propylene glycol	1 year	1 year	Fast-acting, with optimized stabilizers

What are the trends influencing excipient selection?

• Shift toward excipients that enable stable room-temperature storage.
• Preference for excipients derived from GRAS (Generally Recognized as Safe) status.
• Incorporation of biodegradable and biocompatible excipients for targeted delivery.

Key Takeaways

• Formulation stability for Genosyl hinges on antioxidants, stabilizers, buffers, and preservatives.
• Excipient innovation offers avenues for patent extension, product differentiation, and improved shelf life.
• Regulatory compliance requires detailed safety and compatibility data on excipients.
• Strategies include developing lyophilized powders, room-temperature stable solutions, and novel delivery systems.
• Collaborations with excipient developers can accelerate formulation advancements.

FAQs

1. What are the critical excipients influencing Genosyl stability?
   Antioxidants like ascorbic acid and stabilizers such as gelatin or trehalose are key to preventing NO dissociation and myoglobin oxidation.

2. How can excipient innovation extend the product’s market lifespan?
   By developing formulations with novel stabilizers or delivery systems, patents can be broadened, and shelf life improved.

3. Are there regulatory constraints on excipient selection?
   Yes. Excipients must meet safety standards, and any formulation modifications require regulatory filings.

4. What advantages do lyophilized formulations offer over liquid forms?
   They provide enhanced stability, longer shelf life, and ease of storage, especially in outpatient or emergency settings.

5. How does excipient choice influence commercialization speed?
   Well-characterized, regulatory-compliant excipients streamline approval processes and reduce time to market.

---

References

[1] U.S. Food and Drug Administration. (2019). Guidance for Industry: Excipients in Drug Products.
[2] EMA. (2020). Guideline on Excipients in the Labeling and Package Leaflet of Medicinal Products.
[3] Jansen, K. A., & Kettenbach, J. A. (2018). Formulation strategies for nitric oxide-releasing drugs. Journal of Pharmaceutical Sciences.